MedTrace Logo

Once Daily Gabapentin in the Treatment of Post Amputation Pain

NCT01776671 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-09-14

No results posted yet for this study

Summary

Phantom limb pain (PLP) is a common disorder reported by the patients who undergo amputation. Even though the cause of PLP remains unclear, Gabapentin has been widely used. The purpose of this study is to evaluate the accuracy and efficacy achieved in using of extended release Gabapentin. Reducing the incidence of chronic post-amputation pain and improving clinical outcomes postoperatively.

Conditions

  • Pain
  • Quality of Life

Interventions

DRUG

Gralise

Titration starting 300 mg/day up to 1800 mg/day over 2 weeks

Sponsors & Collaborators

  • Chicago Anesthesia Pain Specialists

    lead OTHER

Principal Investigators

  • Kenneth D Candido, M.D. · Chicago Anesthesia Pain Specialists

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2018-11-30
Completion
2018-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01776671 on ClinicalTrials.gov